Literature DB >> 29926429

Targeting Outer Membrane Protein Component AdeC for the Discovery of Efflux Pump Inhibitor against AdeABC Efflux Pump of Multidrug Resistant Acinetobacter baumannii.

Privita Verma1, Vishvanath Tiwari2.   

Abstract

The structure and functioning of multidrug efflux systems provide us with a better understanding of the transport of various antibiotics, thus giving a path for the discovery of effective compounds for combating the multidrug resistance in Acinetobacter baumannii. In the present study, a number of computational techniques have been used to search for an inhibitor for the RND efflux pump, AdeABC, of A. baumannii targeting specifically its outermost component, i.e., AdeC. We have prepared the three-dimensional structure for AdeC using MODELLER v9.16 and identified its active binding site using SiteMap. Using high-throughput virtual screening, we identified compounds from a large library of biogenic compounds on the basis of their effective interaction at the binding site of AdeC. The validation of docking step was performed by plotting ROC curve (enrichment calculations). The docked complexes were further analyzed for their binding free energies by molecular mechanics using Generalized Born model and Solvent Accessibility (MMGBSA). The molecular dynamics simulation was performed for AdeC-ZINC77257599 complex using GROMACS. The present rational drug designing, molecular mechanics and molecular dynamics data provided an inhibitor, i.e, ZINC77257599 [(3R,4Z,6E,8E)-3-hydroxy-2,2,4-trimethyl-10-oxazol-5-yl-deca-4,6,8-trienamide], for the outer membrane protein component (AdeC) of efflux pump AdeABC of A. baumannii.

Entities:  

Keywords:  Acinetobacter baumannii; AdeABC efflux pump; Microbial drug resistance; Molecular dynamics simulation; Outer membrane protein; Virtual screening

Mesh:

Substances:

Year:  2018        PMID: 29926429     DOI: 10.1007/s12013-018-0846-5

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  9 in total

1.  Identification of Promoter Region Markers Associated With Altered Expression of Resistance-Nodulation-Division Antibiotic Efflux Pumps in Acinetobacter baumannii.

Authors:  Mireia López-Siles; Michael J McConnell; Antonio J Martín-Galiano
Journal:  Front Microbiol       Date:  2022-05-19       Impact factor: 6.064

2.  An Evolutionary Conservation and Druggability Analysis of Enzymes Belonging to the Bacterial Shikimate Pathway.

Authors:  Rok Frlan
Journal:  Antibiotics (Basel)       Date:  2022-05-17

3.  Prioritization of potential vaccine targets using comparative proteomics and designing of the chimeric multi-epitope vaccine against Pseudomonas aeruginosa.

Authors:  Vandana Solanki; Monalisa Tiwari; Vishvanath Tiwari
Journal:  Sci Rep       Date:  2019-03-27       Impact factor: 4.379

4.  Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus.

Authors:  Vishvanath Tiwari
Journal:  Int J Biol Macromol       Date:  2021-01-07       Impact factor: 6.953

Review 5.  In Silico Approach for Phytocompound-Based Drug Designing to Fight Efflux Pump-Mediated Multidrug-Resistant Mycobacterium tuberculosis.

Authors:  Santasree Sarma Biswas; Rene Barbie Browne; Vedant Vikrom Borah; Jayanti Datta Roy
Journal:  Appl Biochem Biotechnol       Date:  2021-04-07       Impact factor: 2.926

6.  Targeting and ultrabroad insight into molecular basis of Resistance-nodulation-cell division efflux pumps.

Authors:  Hooria Seyedhosseini Ghaheh; Mohammad Sadegh Damavandi; Parisa Sadeghi; Ahmad Reza Massah; Taravat Hamidi Asl; Azhar Salari-Jazi; Seyed Hossein Hejazi
Journal:  Sci Rep       Date:  2022-09-27       Impact factor: 4.996

Review 7.  Molecular insight into the therapeutic potential of phytoconstituents targeting protein conformation and their expression.

Authors:  Vishvanath Tiwari
Journal:  Phytomedicine       Date:  2018-09-26       Impact factor: 5.340

8.  Novel hybrid antiviral VTRRT-13V2.1 against SARS-CoV2 main protease: retro-combinatorial synthesis and molecular dynamics analysis.

Authors:  Vishvanath Tiwari
Journal:  Heliyon       Date:  2020-09-30

9.  De novo design, retrosynthetic analysis and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2.

Authors:  Vishvanath Tiwari
Journal:  Biol Open       Date:  2020-10-15       Impact factor: 2.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.